SeaStar Medical Holding Corporation (ICU)
NASDAQ: ICU · Real-Time Price · USD
3.920
+0.110 (2.89%)
At close: Apr 28, 2026, 4:00 PM EDT
3.920
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
SeaStar Medical Holding Employees
SeaStar Medical Holding had 17 employees as of December 31, 2025. The number of employees decreased by 2 or -10.53% compared to the previous year.
Employees
17
Change (1Y)
-2
Growth (1Y)
-10.53%
Revenue / Employee
$72,588
Profits / Employee
-$714,706
Market Cap
15.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17 | -2 | -10.53% |
| Dec 31, 2024 | 19 | 7 | 58.33% |
| Dec 31, 2023 | 12 | 3 | 33.33% |
| Dec 31, 2022 | 9 | 6 | 200.00% |
| Dec 31, 2021 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| Theriva Biologics | 16 |
| Lipocine | 14 |
| Genenta Science | 9 |
| Pasithea Therapeutics | 5 |
| Cadrenal Therapeutics | 4 |
ICU News
- 4 weeks ago - SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026 - GlobeNewsWire
- 4 weeks ago - SeaStar Medical Holding Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 6 weeks ago - SeaStar Medical Holding Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 7 weeks ago - SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th - GlobeNewsWire
- 7 weeks ago - SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI - GlobeNewsWire
- 2 months ago - SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI) - GlobeNewsWire